BridgeBio Pharma, Inc. 公布的数据显示,其研究药物Infigratinib在临床研究中展现出良好的耐受性。研究期间,未出现患者因药物原因停药的情况,也未报告任何与研究药物相关的严重不良事件。
BridgeBio Pharma, Inc. 公布的数据显示,其研究药物Infigratinib在临床研究中展现出良好的耐受性。研究期间,未出现患者因药物原因停药的情况,也未报告任何与研究药物相关的严重不良事件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.